BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ma W, Ma J, Ma P, Lei T, Zhao M, Zhang M. Targeting immunotherapy for bladder cancer using anti-CD3× B7-H3 bispecific antibody. Cancer Med 2018;7:5167-77. [PMID: 30253078 DOI: 10.1002/cam4.1775] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Cao G, Zhang G, Liu M, Liu J, Wang Q, Zhu L, Wan X. GPC3-targeted CAR-T cells secreting B7H3-targeted BiTE exhibit potent cytotoxicity activity against hepatocellular carcinoma cell in the in vitro assay. Biochemistry and Biophysics Reports 2022;31:101324. [DOI: 10.1016/j.bbrep.2022.101324] [Reference Citation Analysis]
2 Abd El-Salam MA, Smith CEP, Pan CX. Insights on recent innovations in bladder cancer immunotherapy. Cancer Cytopathol 2022. [PMID: 35653623 DOI: 10.1002/cncy.22603] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Harland N, Maurer FB, Abruzzese T, Bock C, Montes-Mojarro IA, Fend F, Aicher WK, Stenzl A, Amend B. Elevated Expression of the Immune Checkpoint Ligand CD276 (B7-H3) in Urothelial Carcinoma Cell Lines Correlates Negatively with the Cell Proliferation. Int J Mol Sci 2022;23:4969. [PMID: 35563359 DOI: 10.3390/ijms23094969] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Wang L, Hu C, Zhao Y, Hu X. Novel smac mimetic ASTX660 (Tolinapant) and TNF-α synergistically induce necroptosis in bladder cancer cells in vitro upon apoptosis inhibition. Biochemical and Biophysical Research Communications 2022. [DOI: 10.1016/j.bbrc.2022.02.053] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Feng Y, Xie K, Yin Y, Li B, Pi C, Xu X, Huang T, Zhang J, Wang B, Gu H, Fang J. A Novel Anti-B7-H3 × Anti-CD3 Bispecific Antibody with Potent Antitumor Activity. Life 2022;12:157. [DOI: 10.3390/life12020157] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Liu C, Zhang G, Xiang K, Kim Y, Lavoie RR, Lucien F, Wen T. Targeting the immune checkpoint B7-H3 for next-generation cancer immunotherapy. Cancer Immunol Immunother 2021. [PMID: 34739560 DOI: 10.1007/s00262-021-03097-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
7 Aicher WK, Korn M, Reitnauer L, Maurer FB, Hennenlotter J, Black PC, Todenhofer T, Bedke J, Stenzl A. Expression patterns of the immune checkpoint ligand CD276 in urothelial carcinoma. BMC Urol 2021;21:60. [PMID: 33845814 DOI: 10.1186/s12894-021-00829-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
8 Liu Y, Wu Y, Zhang P, Xu C, Liu Z, He C, Liu Y, Kang Z. CXCL12 and CD3E as Indicators for Tumor Microenvironment Modulation in Bladder Cancer and Their Correlations With Immune Infiltration and Molecular Subtypes. Front Oncol 2021;11:636870. [PMID: 33747959 DOI: 10.3389/fonc.2021.636870] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
9 Middelburg J, Kemper K, Engelberts P, Labrijn AF, Schuurman J, van Hall T. Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors. Cancers (Basel) 2021;13:287. [PMID: 33466732 DOI: 10.3390/cancers13020287] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 20.0] [Reference Citation Analysis]
10 Changing Paradigms in the Treatment of Advanced Urothelial Carcinoma: A 2020 Update. EMJ Oncol 2020. [DOI: 10.33590/emj/20-00044] [Reference Citation Analysis]
11 Flem-Karlsen K, Fodstad Ø, Nunes-Xavier CE. B7-H3 Immune Checkpoint Protein in Human Cancer. Curr Med Chem 2020;27:4062-86. [PMID: 31099317 DOI: 10.2174/0929867326666190517115515] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 15.5] [Reference Citation Analysis]
12 Zhou L, Zhao Y. B7-H3 Induces Ovarian Cancer Drugs Resistance Through An PI3K/AKT/BCL-2 Signaling Pathway. Cancer Manag Res 2019;11:10205-14. [PMID: 31819652 DOI: 10.2147/CMAR.S222224] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
13 Sun X, Yu Y, Ma L, Xue X, Gao Z, Ma J, Zhang M. T cell cytotoxicity toward hematologic malignancy via B7-H3 targeting. Invest New Drugs 2020;38:722-32. [PMID: 31267380 DOI: 10.1007/s10637-019-00819-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
14 Ma W, Ma J, Ma P, Lei T, Zhao M, Zhang M. Targeting immunotherapy for bladder cancer using anti-CD3× B7-H3 bispecific antibody. Cancer Med 2018;7:5167-77. [PMID: 30253078 DOI: 10.1002/cam4.1775] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]